Related Experiment Video
Updated: Jul 18, 2025

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
Liang Ye1, Chunmei Li2, Wanglin Jiang3
1School of Public Health and Management, Binzhou Medical University, Yantai, Shandong, China.
Abstract:
Opiates produce analgesia via G-protein signaling, and adverse effects, such as respiratory depression and decreased bowel motility, by β-arrestin pathway. Oliceridine, a G protein-biased MOR agonist, only presents modest safety advantages as compared to other opiates in clinical trials, possibly due to its limited bias. Our previous study shown that LPM3480392, a full MOR biased agonist, is selective for the Gi pathway over the β-arrestin-2. In the present article, we evaluated the subacute toxicity of LPM3480392 in rats. The rats were administered with control article or LPM3480392 0.6, 1.2 or 2.4 mg/kg/day for 4 consecutive weeks followed by a 4-week recovery phase. Intravenous infusion was conducted at tail vein at 0.2, 0.4 or 0.8 mg/kg/day with a dosing volume of 10 mL/kg and 5 min/rat/dose, three times a day with an interval of approximately 4 h. The concomitant toxicokinetics study was conducted. Two unscheduled rats at 2.4 mg/kg/day died with no clear cause. For the scheduled necropsy, the major effects were associated with the MOR agonist-related pharmacodynamic properties of LPM3480392 (e.g., increased activity, increased muscle tone; decreased food consumption and body weight gain; and clinical chemistry changes related with decreased food consumption) in three LPM3480392 groups. In addition, LPM3480392 at 2.4 mg/kg/day also induced deep respiration and histopathology changes in testis and epididymis in sporadic individual rats. However, different from other opiates, LPM3480392 presents weak/no immunosuppression and the decreased adrenal gland weight, which may be due to LPM3480392' full MOR bias. At the end of recovery phase, all findings were recovered to some extent or completely. In the toxicokinetics study, the dose-dependent elevation of drug exposure was observed, which partly explained the toxicity of high dose. In summary, LPM3480392 has exhibited good safety characteristics in this subacute toxicity study in rats.
Insights
LPM3480392, a novel MOR agonist, demonstrated good safety in a rat study. While some dose-dependent effects were observed, they were reversible, indicating favorable characteristics for potential therapeutic use.
Area of Science:
- Pharmacology
- Toxicology
- Drug Development
Background:
- Opiates mediate analgesia via G-protein signaling and adverse effects via β-arrestin pathways.
- Oliceridine, a G protein-biased MOR agonist, shows limited safety advantages, possibly due to its modest bias.
- LPM3480392 is a full MOR biased agonist selective for the Gi pathway over β-arrestin-2.
Purpose of the Study:
- To evaluate the subacute toxicity of LPM3480392 in rats.
- To assess the reversibility of any observed toxic effects.
- To correlate toxicity findings with toxicokinetics.
Main Methods:
- Rats received LPM3480392 (0.6, 1.2, or 2.4 mg/kg/day) or control for 4 weeks, followed by a 4-week recovery.
- Intravenous infusions were administered three times daily.
- Toxicokinetics and histopathology were assessed.
Main Results:
- Major effects were MOR agonist-related (e.g., increased activity, decreased food consumption and body weight gain).
- High dose (2.4 mg/kg/day) induced deep respiration and sporadic testis/epididymis histopathology changes.
- LPM3480392 showed weak/no immunosuppression and decreased adrenal gland weight, with full recovery observed.
Conclusions:
- LPM3480392 exhibits good safety characteristics in this rat subacute toxicity study.
- Observed effects were largely reversible and related to MOR agonism.
- The drug's full MOR bias may contribute to its favorable safety profile.
Related Concept Videos
Opioid Receptors: Overview
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids

